Trials / Completed
CompletedNCT01786096
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-CD19A | SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2017-05-30
- Completion
- 2017-05-30
- First posted
- 2013-02-07
- Last updated
- 2017-07-02
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01786096. Inclusion in this directory is not an endorsement.